These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38039754)

  • 1. Novel ASO therapeutic target designed against hyperlipidemia via PCSK9 knockdown.
    Yu X; Song K
    Biomed Pharmacother; 2024 Jan; 170():115960. PubMed ID: 38039754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.
    Graham MJ; Lemonidis KM; Whipple CP; Subramaniam A; Monia BP; Crooke ST; Crooke RM
    J Lipid Res; 2007 Apr; 48(4):763-7. PubMed ID: 17242417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
    Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM
    PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
    Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
    Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides for the treatment of dyslipidemia.
    Gouni-Berthold I; Berthold HK
    Curr Pharm Des; 2011; 17(9):950-60. PubMed ID: 21418033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
    Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
    Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hyperlipidemia with proprotein convertase subtilisin/kexin type 9 inhibitor in a patient with nephrotic syndrome: a case report.
    Choi HS; Kim CS; Ma SK; Kim SW; Bae EH
    Ann Palliat Med; 2020 Jul; 9(4):2357-2360. PubMed ID: 32648458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.
    Crooke RM; Graham MJ; Lemonidis KM; Whipple CP; Koo S; Perera RJ
    J Lipid Res; 2005 May; 46(5):872-84. PubMed ID: 15716585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats.
    Jia L; Song N; Yang G; Ma Y; Li X; Lu R; Cao H; Zhang N; Zhu M; Wang J; Leng X; Cao Y; Du Y; Xu Y
    Mol Med Rep; 2016 Jun; 13(6):4627-35. PubMed ID: 27082100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.
    Raichur S; Brunner B; Bielohuby M; Hansen G; Pfenninger A; Wang B; Bruning JC; Larsen PJ; Tennagels N
    Mol Metab; 2019 Mar; 21():36-50. PubMed ID: 30655217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo.
    Yang L; Ma F; Liu F; Chen J; Zhao X; Xu Q
    Mol Ther Nucleic Acids; 2020 Mar; 19():1357-1367. PubMed ID: 32160706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(-/-) mice may be associated with increased PCSK9 expression.
    Zhao XS; Wu Q; Peng J; Pan LH; Ren Z; Liu HT; Jiang ZS; Wang GX; Tang ZH; Liu LS
    Mol Med Rep; 2017 Feb; 15(2):712-718. PubMed ID: 28000893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism.
    Watts LM; Manchem VP; Leedom TA; Rivard AL; McKay RA; Bao D; Neroladakis T; Monia BP; Bodenmiller DM; Cao JX; Zhang HY; Cox AL; Jacobs SJ; Michael MD; Sloop KW; Bhanot S
    Diabetes; 2005 Jun; 54(6):1846-53. PubMed ID: 15919808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.